Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal
Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.